Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$1.93 USD

1.93
16,438,753

+0.16 (9.04%)

Updated May 13, 2024 04:00 PM ET

After-Market: $1.93 0.00 (0.00%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -15.63% and 1.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LHC Group (LHCG) Ties Up to Improve Home Health Services

by Zacks Equity Research

LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.

Illumina (ILMN) Invests in Seven Additional Genomics Startups

by Zacks Equity Research

Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.

Why Is Pacific Biosciences (PACB) Down 13.6% Since Last Earnings Report?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PacBio (PACB) Supports SickKids With Sequencing Technology

by Zacks Equity Research

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN

by Debanjana Dey

The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.

DaVita's (DVA) Collaboration to Aid in Kidney Care Needs

by Zacks Equity Research

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.

PacBio (PACB) to Leverage Google's Deep Learning Technologies

by Zacks Equity Research

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues

by Zacks Equity Research

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

Company News for Jan 12, 2022

by Zacks Equity Research

Companies in The News Are: ACCD,PACB,BIG,ILMN

PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability

by Zacks Equity Research

PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.

PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada

by Zacks Equity Research

PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.

PacBio's (PACB) New Surveillance Kit Successful Against Omicron

by Zacks Equity Research

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

by Kevin Cook

Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

by Zacks Equity Research

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis

by Zacks Equity Research

PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.

PacBio's (PACB) New Solution to Boost Public Health Protection

by Zacks Equity Research

PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.

PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.

Pacific Biosciences of California (PACB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -9.52% and 5.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Pacific Biosciences of California (PACB) Q3 Earnings Expected to Decline

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

by Kevin Cook

Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division